Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 17, 2022 in Ampio Lawsuit - AMPE

AMPE

New York, New York--(Newsfile Corp. - August 22, 2022) - Levi & Korsinsky, LLP notifies investors in Ampio Pharmaceuticals, Inc. ("Ampio" or the "Company") (NYSE: AMPE) of a class action securities lawsuit.

The lawsuit on behalf of Ampio investors has been commenced in the the United States District Court for the District of Colorado. This lawsuit is on behalf of all persons or entities that purchased or otherwise acquired Ampio common stock between December 29, 2020 and August 3, 2022, inclusive. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/ampio-lawsuit-submission-form?prid=31082&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/7091/134532_221366_logo.jpg

Ampio Pharmaceuticals, Inc. NEWS - AMPE NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) defendants had inflated the Company's true ability to successfully file a Biologics License Application ("BLA") for Ampion; (ii) defendants had inflated the results of the AP-013 study and the timing of unblinding the data from the AP-013 study; and (iii) as a result of the foregoing, defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Ampio during the relevant timeframe, you have until October 17, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/ampio-lawsuit-submission-form?prid=31082&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/134532



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today